18th November, 2026

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('SEBI Listing Regulations') – exercise of call option to acquire the balance 26% equity stake in Yapan Bio Private Limited

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Administrative Committee of the Board of Directors of Piramal Pharma Limited ('the Company'), acting under the authority delegated by the Board, has approved the exercise of the Company's call option to acquire the balance 26% equity stake in Yapan Bio Private Limited ('Yapan'), a subsidiary of the Company, from its existing shareholders ('the Proposed Transaction').

Consequent to the exercise of the call option, the Company is engaged in discussions with the shareholders of Yapan in relation to matters necessary for consummation of the Proposed Transaction.

The final terms of the acquisition, including the acquisition consideration and the effective date of transfer of shares, are yet to be finalized. The Company will make appropriate disclosures including the details as required under Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Securities Exchange of Board of India Master Circular No. HO/49/14/14(7)2025CFD-POD2/I/3762/2026 dated January 30, 2026, upon execution of definitive documentation and completion of the Proposed Transaction.

Yapan is a Contract Development and Manufacturing Organization that specializes in process development, characterization and Phase I/II GMP manufacturing services for vaccines and biologics.

Upon completion of the proposed transaction the Company's shareholding in Yapan is expected to increase from the existing 74% to 100%, and Yapan will become a wholly owned subsidiary of the Company.

Kindly take the above on record.

Thank you,

Yours truly,
For **Piramal Pharma Limited**

MANEESH SHARMA
Digitally signed by MANEESH SHARMA
Date: 2026.11.18 16:44:28 +05'30'

Maneesh Sharma
Company Secretary & Compliance Officer